GB9800575D0 - Heterocyclic compounds - Google Patents

Heterocyclic compounds

Info

Publication number
GB9800575D0
GB9800575D0 GBGB9800575.4A GB9800575A GB9800575D0 GB 9800575 D0 GB9800575 D0 GB 9800575D0 GB 9800575 A GB9800575 A GB 9800575A GB 9800575 D0 GB9800575 D0 GB 9800575D0
Authority
GB
United Kingdom
Prior art keywords
heterocyclic compounds
heterocyclic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9800575.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB9800575.4A priority Critical patent/GB9800575D0/en
Publication of GB9800575D0 publication Critical patent/GB9800575D0/en
Application status is Ceased legal-status Critical

Links

GBGB9800575.4A 1998-01-12 1998-01-12 Heterocyclic compounds Ceased GB9800575D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB9800575.4A GB9800575D0 (en) 1998-01-12 1998-01-12 Heterocyclic compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9800575.4A GB9800575D0 (en) 1998-01-12 1998-01-12 Heterocyclic compounds
PCT/GB1999/000076 WO1999035132A1 (en) 1998-01-12 1999-01-11 Heterocyclic compounds
AU19786/99A AU1978699A (en) 1998-01-12 1999-02-11 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
GB9800575D0 true GB9800575D0 (en) 1998-03-11

Family

ID=10825157

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9800575.4A Ceased GB9800575D0 (en) 1998-01-12 1998-01-12 Heterocyclic compounds

Country Status (3)

Country Link
AU (1) AU1978699A (en)
GB (1) GB9800575D0 (en)
WO (1) WO1999035132A1 (en)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289791T3 (en) 1997-08-22 2008-02-01 Astrazeneca Ab Oxindolilquinazolina derivatives as angiogenesis inhibitors.
KR100860295B1 (en) * 1998-10-08 2008-09-25 아스트라제네카 아베 Quinazoline derivatives
JP2002527436A (en) 1998-10-08 2002-08-27 アストラゼネカ アクチボラグ Quinazoline derivatives
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CN1167422C (en) 1999-02-10 2004-09-22 阿斯特拉曾尼卡有限公司 Quinazoline derivatives as angiogenesis inhibitors
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
DE60037020T2 (en) 1999-07-09 2008-08-21 Glaxo Group Ltd., Greenford Anilinoquinazolines as protein-tyrosine kinase inhibitor
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
ES2334879T3 (en) * 1999-09-21 2010-03-17 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals.
CN100351241C (en) 1999-11-11 2007-11-28 Osi药物公司 Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, method of production and pharmaceutical uses thereof
WO2001055116A2 (en) * 2000-01-28 2001-08-02 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
SK17102002A3 (en) 2000-06-22 2004-04-06 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
AU6650501A (en) * 2000-06-28 2002-01-08 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
JP2004505964A (en) 2000-08-09 2004-02-26 アストラゼネカ アクチボラグ Quinoline derivatives having Vegf inhibitory activity
JP2004509876A (en) 2000-09-20 2004-04-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトングMerck Patent Gesellschaft mit beschraenkter Haftung 4-Amino - quinazoline
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
EP1777218B1 (en) 2000-10-20 2008-12-31 Eisai R&D Management Co., Ltd. Process for the preparation of 4-phenoxy quinoline derivatives
RS51373B (en) 2001-01-05 2011-02-28 Amgen Fremont Inc. Antibodies to insulin-like growth factor i receptor
PE09582002A1 (en) * 2001-03-23 2002-11-14 Bayer Corp Inhibitors rho kinase
JP4329003B2 (en) * 2001-03-23 2009-09-09 バイエル コーポレイションBayer corporation Rho kinase inhibitor
DE60212487T2 (en) 2001-04-13 2006-12-21 Pfizer Products Inc., Groton Bicyclic substituted 4-Aminopyridopyrimidinderivate
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc CD40 antibodies
US20040014755A1 (en) 2002-01-10 2004-01-22 Dhanapalan Nagarathnam Rho-kinase inhibitors
MXPA04007191A (en) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Pyrimidine derivatives as rho-kinase inhibitors.
WO2003062227A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
ES2381781T3 (en) * 2002-02-01 2012-05-31 Astrazeneca Ab Quinazoline compounds
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
DE60316440T2 (en) 2002-06-14 2008-01-24 Pfizer Inc. Benzo-fused heteroarylamid-derivative compositions of thienopyridines useful as therapeutic agents, corresponding pharmaceutical, and methods for their use
BR0317548A (en) 2002-12-19 2005-11-22 Pfizer indazole compounds and pharmaceutical compositions for the inhibition of protein kinases, and methods for their use
ES2502490T3 (en) 2003-02-26 2014-10-03 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
ES2314444T3 (en) 2003-08-29 2009-03-16 Pfizer Inc. Thienopyridine-fenilacetaminasy their derivatives useful as new anti-angiogenic agents.
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co Antibodies to m-csf
WO2005026156A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
SI1667991T1 (en) 2003-09-16 2008-10-31 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
CA2553423C (en) 2004-01-23 2012-03-20 Amgen Inc. Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
CN1914182B (en) 2004-02-03 2011-09-07 阿斯利康(瑞典)有限公司 Quinazoline derivatives
AP2204A (en) 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
KR100859891B1 (en) 2004-08-26 2008-09-23 화이자 인코포레이티드 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
JP4834553B2 (en) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pharmaceutical compositions
MX2007006230A (en) 2004-11-30 2007-07-25 Amgen Inc Quinolines and quinazoline analogs and their use as medicaments for treating cancer.
JP4881875B2 (en) 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ Pyrazolopyrimidine compounds as antitumor agents
BRPI0609655A2 (en) 2005-03-31 2010-03-16 Agensys Inc antibodies and related molecules that bind to 161P2F10B protein
CA2604357C (en) 2005-04-26 2012-01-17 Pfizer Inc. P-cadherin antibodies
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
JP4989476B2 (en) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for assaying the effects of angiogenesis inhibitors
EP2960253B1 (en) 2005-09-07 2018-06-06 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
ES2354457T3 (en) 2005-09-20 2011-03-15 Astrazeneca Ab Compounds of 4- (1h-indazol-5-il-amino) -chinazoline as inhibitors of the erbb receiver of thyrosine kinase for the treatment of cancer.
CN101003514A (en) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 Derivative of quinazoline, preparation method and usage
MX2008013990A (en) 2006-05-09 2009-01-29 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof.
NL2000613C2 (en) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
WO2007136103A1 (en) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
JP5368096B2 (en) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-tumor agent for undifferentiated gastric cancer
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2007296746B2 (en) 2006-09-11 2012-07-05 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101245050A (en) * 2007-02-14 2008-08-20 上海艾力斯医药科技有限公司 4-aniline quinazoline derivative salt
ES2529790T3 (en) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Methods of treating cancer resistant to therapeutic agents of ERBB
CA2698287A1 (en) 2007-09-07 2009-03-12 Agensys, Inc. Antibodies and related molecules that bind to 24p4c12 proteins
US8080558B2 (en) 2007-10-29 2011-12-20 Natco Pharma Limited 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
US7795254B2 (en) 2007-10-29 2010-09-14 Amgen Inc. Benzomorpholine derivatives and methods of use
WO2009060945A1 (en) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
KR20100111291A (en) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CA2737597C (en) 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
EP2349235A1 (en) 2008-11-07 2011-08-03 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
EP2393814A1 (en) 2009-02-09 2011-12-14 SuperGen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
JP2012519282A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
JP2012519281A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
EP2473500A2 (en) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazole derivatives
US20120316187A1 (en) 2009-11-13 2012-12-13 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2011098971A1 (en) 2010-02-12 2011-08-18 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110217309A1 (en) 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2013538042A (en) 2010-06-16 2013-10-10 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Antibodies against endoplasmin and uses thereof
JP5898074B2 (en) 2010-06-25 2016-04-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Antitumor agent by combined use of compounds having kinase inhibitory action
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
EP2635279A4 (en) * 2010-11-05 2014-10-29 Glaxosmithkline Ip No 2 Ltd Chemical compounds
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
AU2012225232B2 (en) 2011-03-09 2016-05-12 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
BR112013021941A2 (en) 2011-04-18 2016-11-16 Eisai R&D Man Co Ltd tumor therapeutic agent
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
JP6038128B2 (en) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds
EP3409278A1 (en) 2011-07-21 2018-12-05 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CN104024432B (en) 2011-08-31 2017-02-22 基因泰克公司 Diagnostic markers
SG2014014450A (en) 2011-09-22 2014-09-26 Pfizer Pyrrolopyrimidine and purine derivatives
EP2761025A1 (en) 2011-09-30 2014-08-06 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
AU2011378675B2 (en) 2011-10-04 2017-10-05 Igem Therapeutics Limited IgE anti -HMW-MAA antibody
EP2776467A1 (en) 2011-11-08 2014-09-17 Pfizer Inc Methods of treating inflammatory disorders using anti-m-csf antibodies
WO2013096151A1 (en) * 2011-12-22 2013-06-27 Glaxosmithkline Llc Chemical compounds
WO2013096153A1 (en) * 2011-12-22 2013-06-27 Glaxosmithkline Llc Chemical compounds
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013173312A1 (en) 2012-05-14 2013-11-21 Pestell Richard G Using modulators of ccr5 for treating cancer
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
MX2015004979A (en) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Amorphous form of quinoline derivative, and method for producing same.
JP6255038B2 (en) 2013-02-26 2017-12-27 トリアクト セラピューティクス,インク. Cancer treatment
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
KR20160058960A (en) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 Compositions and methods for treating cancers
KR101919672B1 (en) 2013-11-21 2018-11-16 화이자 인코포레이티드 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
CA2947130C (en) 2014-04-30 2018-10-02 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3177320A4 (en) 2014-07-31 2018-05-16 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Human monoclonal antibodies against epha4 and their use
CN106660964A (en) 2014-08-28 2017-05-10 卫材R&D管理有限公司 High-purity quinoline derivative and method for manufacturing same
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
KR20180100125A (en) 2015-12-03 2018-09-07 아지오스 파마슈티컬스 아이엔씨. MAT2A inhibitor for treating MTAP null cancer
AU2017379847A1 (en) 2016-12-19 2019-08-01 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20180334454A1 (en) 2017-05-22 2018-11-22 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190077801A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (en) * 1995-10-11 1998-09-30 Glaxo Group Ltd heterocyclic compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives

Also Published As

Publication number Publication date
WO1999035132A1 (en) 1999-07-15
AU1978699A (en) 1999-07-26

Similar Documents

Publication Publication Date Title
EG24743A (en) Heterocyclic compounds.
EG24041A (en) New heterocyclic compounds
GB9819847D0 (en) Novel compounds
GB9803411D0 (en) Novel compounds
PL354998A1 (en) Substituted oxoazaheterocyclyl compounds
GB9801392D0 (en) Novel compounds
HRP970371A2 (en) Heterocyclic compounds
GB9818731D0 (en) Compounds
PL353156A1 (en) Compounds
IL134086D0 (en) Novel spiroazabicyclic heterocyclic compounds
AU1978699A (en) Heterocyclic compounds
GB9602294D0 (en) Heterocyclic compounds
GB9804734D0 (en) Compounds
IL132170D0 (en) Novel heterocyclic compounds
GB9929973D0 (en) Heterocyclic compounds
GB9819681D0 (en) Novel compounds
GB9804175D0 (en) Compounds
GB9808327D0 (en) Antidiotypic compounds
GB9715892D0 (en) Heterocyclic compounds
GB9617305D0 (en) Heterocyclic compounds
GB9815163D0 (en) Compounds
GB9810193D0 (en) Novel compounds
GB9816984D0 (en) Novel compounds
GB9810276D0 (en) Novel compounds
GB9922519D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)